CO2021000188A2 - Anticuerpos anti-bcma x anti-cd3 biespecíficos y usos de estos - Google Patents

Anticuerpos anti-bcma x anti-cd3 biespecíficos y usos de estos

Info

Publication number
CO2021000188A2
CO2021000188A2 CONC2021/0000188A CO2021000188A CO2021000188A2 CO 2021000188 A2 CO2021000188 A2 CO 2021000188A2 CO 2021000188 A CO2021000188 A CO 2021000188A CO 2021000188 A2 CO2021000188 A2 CO 2021000188A2
Authority
CO
Colombia
Prior art keywords
bcma
bispecific
antibodies
cells
useful
Prior art date
Application number
CONC2021/0000188A
Other languages
English (en)
Inventor
Frank Delfino
Eric Smith
Kara Olson
David Dilillo
Jessica Kirshner
Olga Sineshchekova
Qian Zhang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO2021000188A2 publication Critical patent/CO2021000188A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

RESUMEN El antígeno de maduración de células B (BCMA) se expresa en células plasmáticas malignas. La presente invención proporciona anticuerpos biespecíficos (bsAbs) novedosos que se unen a BCMA y CD3 y activan las células T a través del complejo CD3 en presencia de células tumorales que expresan BCMA. En determinadas modalidades, las moléculas de unión a antígeno biespecíficas de la presente invención pueden inhibir el crecimiento de tumores que expresan BCMA. Las moléculas de unión a antígeno biespecíficas de la invención son útiles para el tratamiento de enfermedades y trastornos en los que se desea y/o es terapéuticamente beneficiosa una respuesta inmunitaria dirigida a BCMA inducida o regulada de manera ascendente. Por ejemplo, los anticuerpos biespecíficos de la invención son útiles para el tratamiento de diversos tipos de cáncer, que incluyen mieloma múltiple.
CONC2021/0000188A 2018-07-19 2021-01-13 Anticuerpos anti-bcma x anti-cd3 biespecíficos y usos de estos CO2021000188A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862700596P 2018-07-19 2018-07-19
US201862750968P 2018-10-26 2018-10-26
US201962793645P 2019-01-17 2019-01-17
PCT/US2019/042447 WO2020018820A1 (en) 2018-07-19 2019-07-18 BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
CO2021000188A2 true CO2021000188A2 (es) 2021-01-18

Family

ID=67515169

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0000188A CO2021000188A2 (es) 2018-07-19 2021-01-13 Anticuerpos anti-bcma x anti-cd3 biespecíficos y usos de estos

Country Status (16)

Country Link
US (2) US11384153B2 (es)
EP (1) EP3823664A1 (es)
JP (2) JP7319348B2 (es)
KR (1) KR20210034032A (es)
CN (1) CN112423785A (es)
AU (1) AU2019307928A1 (es)
BR (1) BR112021000186A2 (es)
CA (1) CA3107126A1 (es)
CL (1) CL2021000131A1 (es)
CO (1) CO2021000188A2 (es)
IL (1) IL279974A (es)
MA (1) MA53168A (es)
MX (1) MX2021000488A (es)
PH (1) PH12021550031A1 (es)
SG (1) SG11202100252SA (es)
WO (1) WO2020018820A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ759513A (en) 2017-06-01 2022-01-28 Regeneron Pharma Human antibodies to bet v 1 and methods of use thereof
EP4069373A1 (en) 2019-12-06 2022-10-12 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies
TW202144425A (zh) * 2020-04-17 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 特異性抗原結合分子，其製備方法及醫藥用途
KR20230030573A (ko) 2020-07-01 2023-03-06 리제너론 파마슈티칼스 인코포레이티드 항-bet v1 항체를 사용하여 알러지를 치료하는 방법
US20230398147A1 (en) 2020-09-16 2023-12-14 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
JP2023543152A (ja) 2020-09-18 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用
CN114524878A (zh) 2020-11-23 2022-05-24 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
CN114573703A (zh) 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种t细胞衔接器治疗剂的开发和应用
WO2022120388A2 (en) 2020-12-04 2022-06-09 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
TW202246333A (zh) * 2021-01-20 2022-12-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｂｃｍａ和ｃｄ３的抗原結合分子及其醫藥用途
US20220233690A1 (en) 2021-01-28 2022-07-28 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
WO2023122138A1 (en) * 2021-12-22 2023-06-29 The Jackson Laboratory Humanized mouse models
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN117003871A (zh) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
WO2023225098A1 (en) 2022-05-18 2023-11-23 Regeneron Pharmaceuticals, Inc. Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
US20240002331A1 (en) 2022-06-08 2024-01-04 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2024081180A1 (en) 2022-10-10 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for reducing alloantibody levels in subjects in need of solid organ transplantation
CN117186230B (zh) * 2022-12-06 2024-04-16 成都赛恩吉诺生物科技有限公司 包含亲水性氨基酸的抗人bcma纳米抗体的双特异性抗体及应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR20090016772A (ko) 1999-08-17 2009-02-17 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
DE10206325A1 (de) 2002-02-14 2003-09-04 Medinnova Ges Med Innovationen Ummantelter Mikroorganismus
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
US7582298B2 (en) 2006-06-02 2009-09-01 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
EP3141562A1 (en) 2009-03-10 2017-03-15 Biogen MA Inc. Anti-bcma antibodies
EP2445936A1 (en) 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
EP2501817B2 (en) 2010-02-08 2021-04-21 Regeneron Pharmaceuticals, Inc. Common light chain mouse
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
TWI807362B (zh) 2010-11-30 2023-07-01 日商中外製藥股份有限公司 細胞傷害誘導治療劑
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US10189906B2 (en) 2012-11-01 2019-01-29 Max-Delrück-Centrum Für Molekulare Medizin Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3620468A1 (en) 2013-02-05 2020-03-11 EngMab Sàrl Method for the selection of antibodies against bcma
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
US20180112384A1 (en) 2013-12-30 2018-04-26 Craig Rothleitner Drainage treatment system
MX2016013767A (es) 2014-04-30 2017-04-06 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Anticuerpos humanizados contra cd269 (bcma).
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
PL3221357T3 (pl) 2014-11-20 2020-11-02 F. Hoffmann-La Roche Ag Wspólne łańcuchy lekkie i sposoby zastosowania
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
CN113388036A (zh) 2014-12-05 2021-09-14 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的抗体及其用途
EP3227432B1 (en) 2014-12-05 2023-10-11 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
KR102405104B1 (ko) 2015-04-13 2022-06-07 화이자 인코포레이티드 치료 항체 및 그의 용도
AU2016263198C1 (en) 2015-05-15 2023-10-05 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
HUE050556T2 (hu) 2015-08-17 2020-12-28 Janssen Pharmaceutica Nv Anti-BCMA ellenanyagok, BCMA-t és CD3-at kötõ bispecifikus antigénkötõ molekulák és ezek alkalmazásai
HUE057683T2 (hu) 2015-09-23 2022-05-28 Regeneron Pharma Optimalizált anti-CD3 bispecifikus antitestek és alkalmazásaik
CA3005042A1 (en) 2015-11-13 2017-05-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-bcma polypeptides and proteins
RU2018123717A (ru) 2015-12-01 2020-01-14 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Комбинированные лечения, их применения и способы
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
HUE057220T2 (hu) 2016-02-03 2022-04-28 Amgen Res Munich Gmbh BCMA és CD3 bispecifikus, T-sejtet kötõ antitest-konstrukciók
EP3416687A4 (en) 2016-02-17 2019-10-23 Seattle Genetics, Inc. BCMA ANTIBODIES AND USE THEREOF FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL ILLNESSES
WO2018009904A2 (en) 2016-07-08 2018-01-11 Tumeh Paul C Compositions and treatment methods for cancer immunotherapy
CR20190198A (es) 2016-09-14 2019-10-11 Teneobio Inc Anticuerpos de unión a cd3
MY194596A (en) * 2016-09-23 2022-12-06 Regeneron Pharma Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates
WO2018075359A1 (en) 2016-10-18 2018-04-26 Boger Henry William Wireless power transfer for process control
BR112019008426A2 (pt) 2016-11-02 2019-09-03 Engmab Sarl anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo
BR112019010878A2 (pt) 2016-11-29 2019-10-01 Lindhofer Horst combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos
MX2019007379A (es) 2016-12-21 2019-09-18 Teneobio Inc Anticuerpos anti-bcma unicamente de cadena pesada.
IL268206B2 (en) 2017-01-23 2024-05-01 Carsgen Therapeutics Co Ltd Antibodies directed against BCMA and their use
JP7231549B2 (ja) 2017-02-06 2023-03-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法
CN117357638A (zh) 2017-02-17 2024-01-09 弗雷德哈钦森癌症中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
AU2018261951A1 (en) 2017-05-05 2019-10-31 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
KR20200035066A (ko) 2017-08-01 2020-04-01 메디뮨 엘엘씨 Bcma 단클론 항체-약물 접합체
AU2018341541B2 (en) 2017-09-29 2021-12-23 Dana‐Farber Cancer Institute, Inc. Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same
BR112020007196A2 (pt) 2017-10-13 2020-12-01 Harpoon Therapeutics, Inc. proteínas triespecíficas e métodos de uso
US11026975B2 (en) 2018-02-01 2021-06-08 Nanjing Iaso Biotherapeutics Co., Ltd. Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
BR112020023508A2 (pt) * 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
AU2020240132A1 (en) * 2019-03-21 2021-09-16 Regeneron Pharmaceuticals, Inc. Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy

Also Published As

Publication number Publication date
PH12021550031A1 (en) 2021-09-20
US20200024356A1 (en) 2020-01-23
US11384153B2 (en) 2022-07-12
JP2023134728A (ja) 2023-09-27
CN112423785A (zh) 2021-02-26
JP7319348B2 (ja) 2023-08-01
EP3823664A1 (en) 2021-05-26
WO2020018820A1 (en) 2020-01-23
JP2021531005A (ja) 2021-11-18
MX2021000488A (es) 2021-04-12
MA53168A (fr) 2021-05-26
IL279974A (en) 2021-03-01
US20220306758A1 (en) 2022-09-29
BR112021000186A2 (pt) 2021-08-10
CL2021000131A1 (es) 2021-07-02
CA3107126A1 (en) 2020-01-23
SG11202100252SA (en) 2021-02-25
AU2019307928A1 (en) 2021-02-11
TW202019966A (zh) 2020-06-01
KR20210034032A (ko) 2021-03-29

Similar Documents

Publication Publication Date Title
CL2021000131A1 (es) Anticuerpos anti-bcma x anti-cd3 biespecíficos y usos de estos.
CL2023002690A1 (es) Anticuerpos anti-muc16-cd3 biespecíficos y conjugados anti-muc16-fármacos (divisional de 202102645)
CL2020003179A1 (es) (divisional de solicitud 713-2015) anticuerpos anti-cd3, moleculas de union a antígeno biespecificas que se unen a cd3 y cd20; y usos de los mismos.
CO2019003923A2 (es) Anticuerpos anti-steap2, conjugados anticuerpo-fármaco, y moléculas de fijación al antígeno biespecíficas que se fijan a steap2 y cd3, y usos de estos
CL2022003796A1 (es) Receptores antigénicos quiméricos con especificidad para bcma y usos de estos
CL2020003285A1 (es) Anticuerpos anti-psma x anti-cd28 biespecificos y usos de estos.
AR106570A1 (es) Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos
CO2021009004A2 (es) Anticuerpos biespecíficos anti-cd28 x anti-cd22 y usos de estos
CO2021007077A2 (es) Anticuerpos anti-muc16 x anti-cd28 biespecíficos y usos de estos
CO2020008940A2 (es) Anticuerpos de unión a gprc5d
PE20210287A1 (es) Anti-cd25 para el agotamiento de celulas tumorales especificas
PE20180046A1 (es) Anticuerpos terapeuticos y sus usos
BR112018072986A2 (pt) anticorpos anti-pd-1 e anti-lag3 para tratamento de câncer
ECSP20075198A (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos
PE20210488A1 (es) Anticuerpos especificos para gucy2c y sus usos
MX2018003403A (es) Anticuerpos biespecificos anti-cd3 optimizados y sus usos.
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?
MX2020004573A (es) Terapia de combinacion con agonistas de ox40 dirigidos.
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
CO2023004448A2 (es) Moléculas de unión a antígeno que se unen a cd38 y/o cd28, y usos de estas
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
CL2019002735A1 (es) Anticuerpos que se unen a steap-1.
CL2021000146A1 (es) Anticuerpos humanizados contra psma
CO2023016595A2 (es) Receptores de antígenos quiméricos con especificidad para mage-a4 y usos de estos
EA202190314A1 (ru) Биспецифические анти-bcma x анти-cd3 антитела и способы их применения